Vision, Integrity, Expertise
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Dr. Christopher Schaber, President & CEO of Soligenix Inc. talks about the company’s activities.
Video provided courtesy of Thomson Reuters Insider Network
Latest News Latest News
Monday, July 25th, 2016
Relevant Publications Publications
Monday, June 13th, 2016
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of oncology, supportive cancer care, gastrointestinal and biodefense.